Sunday, July 26, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $333.02 +3.53%
MSFT $381.70 +0.03%
GOOGL $319.74 +0.65%
AMZN $232.11 -0.66%
TSLA $313.03 -2.08%
META $595.19 -1.80%
NVDA $206.84 -0.92%
JPM $353.21 +0.95%
BTC $28.37 -0.94%
ETH $17.75 -0.62%
AAPL
$333.02
▲ 3.53%
MSFT
$381.70
▲ 0.03%
GOOGL
$319.74
▲ 0.65%
AMZN
$232.11
▼ 0.66%
TSLA
$313.03
▼ 2.08%
META
$595.19
▼ 1.80%
NVDA
$206.84
▼ 0.92%
JPM
$353.21
▲ 0.95%
Bloomberg Markets
Wall Street traders drove stocks down from the brink of all-time highs as a renewed slide in SpaceX overshadowed optimism about progress in peace talks between the US and Iran. Mamadou-Abou Sarr, President & Co-Founder of V-Square Quantitative Management discusses the markets and how he is encouraging diversified investing. (Source: Bloomberg)
business  Jun 22, 2026
Bloomberg Markets
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to co
business  Jun 22, 2026
Bloomberg Markets
Alamos Gold CEO John McCluskey joins Bloomberg Open Interest to explain the seismic disruption behind the company’s production cut, why he sees the setback as temporary, and why he rejects the idea that a weaker share price makes Alamos an M&A target. (Source: Bloomberg)
business  Jun 22, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free